Company Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 13, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Tien-Li Lee |
Contact Details
Address: 4370 La Jolla Village Drive, Suite 1050 San Diego, California 92122 United States | |
| Phone | 858 225 7696 |
| Website | aardvarktherapeutics.com |
Stock Details
| Ticker Symbol | AARD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001774857 |
| Employer ID | 82-1606367 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tien-Li Lee, M.D. | Chief Executive Officer and Director |
| Manasi Jaiman, M.D., M.P.H. | Chief Medical Officer |
| Bryan Jones, Ph.D. | Chief Operating Officer |
| Nelson Sun | Chief Financial Officer |
| Jeffrey Chi, Ph.D. | Lead Independent Director |
| Roy D. Baynes, M.D., Ph.D. | Director |
| Susan E. Graf | Director |
| Victor Tong, Jr. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | 8-K | Current Report |
| Feb 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2025 | 424B4 | Prospectus |
| Feb 12, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | CERT | Certification by an exchange approving securities for listing |
| Feb 10, 2025 | 8-A12B | Registration of securities |
| Feb 6, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 23, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 23, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 27, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |